| Interleukin-6 receptor antagonists in critically ill patients with Covid-19 Remap-Cap Investigators New England Journal of Medicine 384 (16), 1491-1502, 2021 | 1978 | 2021 |
| Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19 ATTACC, ACTIV-4a, and REMAP-CAP Investigators New England Journal of Medicine 385 (9), 790-802, 2021 | 879* | 2021 |
| Plasmodium vivax in the era of the shrinking P. falciparum map RN Price, RJ Commons, KE Battle, K Thriemer, K Mendis Trends in parasitology 36 (6), 560-570, 2020 | 224 | 2020 |
| Streptococcal superantigens: categorization and clinical associations RJ Commons, PR Smeesters, T Proft, JD Fraser, R Robins-Browne, ... Trends in molecular medicine 20 (1), 48-62, 2014 | 152 | 2014 |
| Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ... Jama 329 (1), 39-51, 2023 | 120 | 2023 |
| The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta … RJ Commons, JA Simpson, K Thriemer, GS Humphreys, T Abreha, ... The Lancet Infectious Diseases 18 (9), 1025-1034, 2018 | 117 | 2018 |
| Estimating the proportion of Plasmodium vivax recurrences caused by relapse: a systematic review and meta-analysis RJ Commons, JA Simpson, J Watson, NJ White, RN Price The American journal of tropical medicine and hygiene 103 (3), 1094, 2020 | 112 | 2020 |
| Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial YM Arabi, AC Gordon, LPG Derde, AD Nichol, S Murthy, FA Beidh, ... Intensive care medicine 47, 867-886, 2021 | 105 | 2021 |
| Superantigen genes in group A streptococcal isolates and their relationship with emm types R Commons, S Rogers, T Gooding, M Danchin, J Carapetis, ... Journal of medical microbiology 57 (10), 1238-1246, 2008 | 99 | 2008 |
| Effect of antiplatelet therapy on survival and organ support–free days in critically ill patients with COVID-19: a randomized clinical trial CA Bradbury, PR Lawler, SJ Stanworth, BJ McVerry, Z McQuilten, ... Jama 327 (13), 1247, 2022 | 97 | 2022 |
| Strain prevalence, rather than innate virulence potential, is the major factor responsible for an increase in serious group A streptococcus infections S Rogers, R Commons, MH Danchin, G Selvaraj, L Kelpie, N Curtis, ... The Journal of infectious diseases 195 (11), 1625-1633, 2007 | 96 | 2007 |
| Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis RJ Commons, JA Simpson, K Thriemer, MS Hossain, NM Douglas, ... The Lancet Infectious Diseases 19 (1), 91-101, 2019 | 86 | 2019 |
| Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group K Thriemer, B Ley, A Bobogare, L Dysoley, MS Alam, AP Pasaribu, ... Malaria journal 16, 1-9, 2017 | 80 | 2017 |
| High burden of diabetic foot infections in the top end of Australia: an emerging health crisis (DEFINE study) RJ Commons, CH Robinson, D Gawler, JS Davis, RN Price Diabetes research and clinical practice 110 (2), 147-157, 2015 | 73 | 2015 |
| Genetic diversity of the msp-1, msp-2, and glurp genes of Plasmodium falciparum isolates in Northwest Ethiopia H Mohammed, M Kassa, K Mekete, A Assefa, G Taye, RJ Commons Malaria journal 17, 1-8, 2018 | 54 | 2018 |
| Therapeutic anticoagulation in critically ill patients with Covid-19–preliminary report REMAP-CAP, ACTIV-4a, ATTACC Investigators, R Zarychanski MedRxiv, 2021.03. 10.21252749, 2021 | 52 | 2021 |
| Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19: a randomized … S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, K Fareed, ... Jama 329 (14), 1183-1196, 2023 | 44 | 2023 |
| The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance … RJ Commons, JA Simpson, K Thriemer, CS Chu, NM Douglas, T Abreha, ... BMC medicine 17, 1-13, 2019 | 42 | 2019 |
| The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance … MS Hossain, RJ Commons, NM Douglas, K Thriemer, BH Alemayehu, ... PLoS medicine 17 (11), e1003393, 2020 | 41 | 2020 |
| The Vivax Surveyor: online mapping database for Plasmodium vivax clinical trials RJ Commons, K Thriemer, G Humphreys, I Suay, CH Sibley, PJ Guerin, ... International Journal for Parasitology: Drugs and Drug Resistance 7 (2), 181-190, 2017 | 41 | 2017 |
Ric PriceThe University of Oxford / Menzies School of Health, DarwinПотвърден имейл адрес: menzies.edu.au